98 Participants Needed

Decision Aid for Lung Cancer

Recruiting at 1 trial location
Age: Any Age
Sex: Any
Trial Phase: Academic
Sponsor: OHSU Knight Cancer Institute
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

This trial tests a tool that helps lung cancer patients understand their treatment options and make decisions with their doctors. It aims to improve patient knowledge, reduce uncertainty, and enhance communication. The study evaluates the tool's effectiveness.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It focuses on decision-making for lung cancer treatment, so it's best to discuss your medications with the trial team.

What data supports the effectiveness of the Decision Aid for Lung Cancer treatment?

Research shows that using decision aids for lung cancer treatment helps patients better understand their treatment options and reduces their uncertainty about making decisions. In a pilot study, patients using a decision aid expressed clear treatment preferences and had less concern about treatment costs.12345

Is the Decision Aid treatment safe for humans?

The Decision Aid treatment, used to help patients make informed choices about their lung cancer treatment options, has been tested in a small group of patients and was found to increase awareness of treatment options and reduce concerns about costs and decision-making uncertainty. However, more studies are needed to fully understand its safety and effectiveness in clinical care.13567

How does the decision aid treatment for lung cancer differ from other treatments?

The decision aid for lung cancer is unique because it focuses on helping patients make informed choices about their treatment options by providing personalized information and supporting shared decision-making with their doctors. Unlike traditional treatments that focus solely on medical interventions, this aid empowers patients to weigh the benefits and risks of different treatments, especially in non-curative settings where quality of life and potential side effects are significant considerations.4891011

Research Team

DS

Donald Sullivan

Principal Investigator

OHSU Knight Cancer Institute

Eligibility Criteria

This trial is for English-speaking individuals with a life expectancy over 6 months who have completed treatment or are undergoing diagnostic work-up for suspected or confirmed stage I-IV non-small cell lung cancer. They must also be cognitively able to participate, as indicated by a score above 3 on a specific cognitive screener.

Inclusion Criteria

I am being tested for suspected lung cancer at any stage.
You are expected to live for at least 6 more months.
I have completed treatment for early or advanced non-small cell lung cancer.
See 2 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants are randomized to receive either the conversation tool or usual care

4-8 weeks
1 visit (in-person) at baseline

Follow-up

Participants are monitored for outcomes such as anxiety, decisional conflict, and shared decision-making quality

4-8 weeks
1 visit (in-person or virtual) for follow-up questionnaire

Treatment Details

Interventions

  • Decision Aid
Trial OverviewThe study tests the effectiveness of a decision aid designed to improve decision-making in patients with non-small cell lung cancer. It aims to see if this tool helps patients understand their condition better and make more informed choices about their care alongside their doctors.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Arm I (conversation tool)Experimental Treatment2 Interventions
Patients receive the conversation tool.
Group II: Arm II (usual care)Active Control2 Interventions
Patients receive usual care.

Find a Clinic Near You

Who Is Running the Clinical Trial?

OHSU Knight Cancer Institute

Lead Sponsor

Trials
239
Recruited
2,089,000+

Hildegard Lamfrom Endowment

Collaborator

Trials
1
Recruited
100+

Medical Research Foundation, Oregon

Collaborator

Trials
14
Recruited
1,100+

ATS Foundation

Collaborator

Trials
1
Recruited
100+

Oregon Health and Science University

Collaborator

Trials
1,024
Recruited
7,420,000+

Findings from Research

A novel decision support intervention (DSI) for patients with late-stage non-small cell lung cancer (NSCLC) was developed, which includes care plan cards and a patient preference tool to facilitate shared decision making about treatment options.
Pilot testing with five patients showed that using the DSI increased awareness of treatment options and their benefits/risks, while reducing concerns about treatment costs and decision-making uncertainty, indicating its potential effectiveness in clinical settings.
Engaging Patients with Late-Stage Non-Small Cell Lung Cancer in Shared Decision Making about Treatment.Myers, RE., Advani, SM., Myers, P., et al.[2021]
A single-page, paper-based encounter decision aid (EDA) used during shared decision-making visits for lung cancer screening significantly reduced patient decisional conflict, as indicated by a drop in the Decisional Conflict Scale score from 35.0 to 0.2 (p < 0.001).
While 28% of patients understood the mortality benefit of lung cancer screening after the visit, a much higher percentage (82%) grasped the frequency of abnormal screening results, highlighting the need for improved patient education on the mortality benefits of screening.
Pilot Study of an Encounter Decision Aid for Lung Cancer Screening.Ito Fukunaga, M., Balwan, A., Janis, JA., et al.[2023]
In a study involving 237 lung cancer screening patients, both Option Grids and Shouldiscreen.com were effective in facilitating shared decision making (SDM), but Option Grids led to lower decision regret and better understanding of potential complications compared to Shouldiscreen.com.
Patients using Shouldiscreen.com reported less knowledge about complications and had higher decision regret regarding their choice to pursue screening, highlighting the importance of the decision aid used in the SDM process.
Aiding shared decision making in lung cancer screening: two decision tools.Sferra, SR., Cheng, JS., Boynton, Z., et al.[2021]

References

Engaging Patients with Late-Stage Non-Small Cell Lung Cancer in Shared Decision Making about Treatment. [2021]
Pilot Study of an Encounter Decision Aid for Lung Cancer Screening. [2023]
Decision support systems for incurable non-small cell lung cancer: a systematic review. [2023]
Challenges for designing and implementing decision aids. [2007]
Aiding shared decision making in lung cancer screening: two decision tools. [2021]
Development and validation of a web-based patient decision aid for immunotherapy for patients with metastatic melanoma: study protocol for a multicenter randomized trial. [2021]
A prospective cohort study of shared decision making in lung cancer diagnostics: Impact of using a patient decision aid. [2020]
Evaluation of a Personalized, Web-Based Decision Aid for Lung Cancer Screening. [2018]
HELP - Heidelberg decision aid for lung cancer patients: a randomized controlled clinical trial. [2023]
The development of a decision aid to support Hodgkin lymphoma survivors considering lung cancer screening. [2022]
Development and testing of "Is Lung Cancer Screening for You?" A computer-based decision aid. [2023]